An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family
Zhang Baoshan, Barnes Shannon, Craigo Jodi K and 4 more
Retrovirology · 2009
doi:10.1186/1742-4690-6-95 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background Equine infectious anemia virus (EIAV), a lentivirus that infects horses, has been utilized as an animal model for the study of HIV. Furthermore, the disease associated with the equine lentivirus poses a significant challenge to veterinary medicine around the world. As with all lentiviruses, EIAV has been shown to have a high propensity for genomic sequence and antigenic variation, especially in its envelope (Env) proteins. Recent studies have demonstrated Env variation to be a major determinant of vaccine efficacy, emphasizing the importance of defining natural variation among field isolates of EIAV. To date, however, published EIAV sequences have been reported only for cell-adapted strains of virus, predominantly derived from a single primary virus isolate, EIAV Wyoming (EIAV WY ). Results We present here the first characterization of the Env protein of a natural primary isolate from Pennsylvania (EIAV PA ) since the widely utilized and referenced EIAV WY strain. The data demonstrated that the level of EIAV PA Env amino acid sequence variation, approximately 40% as compared to EIAV WY , is much greater than current perceptions or published reports of natural EIAV variation between field isolates. This variation did not appear to give rise to changes in the predicted secondary structure of the proteins. While the EIAV PA Env was serologically cross reactive with the Env proteins of the cell-adapted reference strain, EIAV PV (derivative of EIAV WY ), the two variant Envs were shown to lack any cross neutralization by immune serum from horses infected with the respective virus strains. Conclusion Taking into account the significance of serum neutralization to universal vaccine efficacy, these findings are crucial considerations towards successful EIAV vaccine development and the potential inclusion of field isolate Envs in vaccine candidates.
Abstract licence: CC BY-NC-ND
References62
62 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.